KOSDAQIT & Software099750

ezCaretech

₩6,280▲ 2.28%2026-11-18 close
Market Cap
₩85.8B
Turnover
₩46,212,330
Volume
7.5K
Shares out.
13.7M
PER
24.6×
PBR
1.9×
EPS
₩247
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

From HIS Projects to Platform: Profit Recovery Amid Quarterly Swings

ezCaretech's operating profit and profit attributable to controlling shareholders have risen for two consecutive fiscal years through March 2026, but the third quarter of 2026 swung to a net loss attributable to controlling shareholders of KRW 1.14 billion, leaving proof of the platform shift as the central test.

  1. 1

    Revenue for the fiscal year ended March 2026 was KRW 78.9 billion, up 8.6% year on year, and operating profit was KRW 5.02 billion, up 127.0%, the largest year in the period covered by the filings.

  2. 2

    Profit attributable to controlling shareholders turned positive in the fiscal year ended March 2024 and then rose to KRW 2.29 billion and KRW 6.09 billion, while operating cash flow in fiscal 2026 turned negative at -KRW 1.24 billion.

  3. 3

    Third-quarter 2026 revenue was KRW 21 billion, up 22.8% year on year, but operating profit fell 35.7% to KRW 1.37 billion and the company posted a net loss attributable to controlling shareholders of KRW 1.14 billion.

  4. 4

    The company targets a platform revenue share of 50% or more by 2030, versus 18% for the fiscal year ended March 2026, and platform revenue for April to June 2026 rose from KRW 1.7 billion to KRW 3.7 billion.

  5. 5

    Overseas revenue was KRW 9.8 billion in the fiscal year ended March 2026, and the company has set a target of more than KRW 20 billion for the fiscal year ending March 2027, which is the next checkpoint.

02

Business structure

ezCaretech builds, operates and maintains hospital information systems (HIS). For large hospitals it installs the on-premise HIS BESTCare, while for small and mid-sized hospitals it offers the cloud-based EDGE&NEXT.

When the company reported its 2024 third-quarter results, it said its domestic on-premise HIS business accounted for about 85% of total revenue. Installation revenue tends to cluster around contract timing and build periods, which is why the company is pushing platform business with recurring revenue.

Platform revenue was 18% of the total for the fiscal year ended March 2026. Overseas revenue was KRW 9.8 billion in the same fiscal year, built mainly on public and private hospital projects in Saudi Arabia, with activity also in Japan and the United States.

In Korea, the company is building next-generation HIS systems for six veterans hospitals and three long-term care hospitals. The company says its on-premise and cloud HIS products are used at 89 hospitals and that it has integrated 50 solutions from 40 external partners.

In September 2026 it announced inclusion in the 2026 World's Top HealthTech Companies list published by TIME and Statista. The claim that it is the only company able to cover both large and small-to-mid hospitals is the company's own position.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩17.1B₩2.1B12.4%
2025Q4₩19.8B₩1.1B5.4%
2026Q1₩26.1B₩1.7B6.6%
2026Q2₩20.5B₩300M1.4%
2026Q3₩21B₩1.4B6.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023.03₩73.2B-₩4.1B-₩9.6B−5.6%−28.1%73.5%
2024.03₩67.9B₩200M₩1.2B0.3%3.5%34.7%
2025.03₩72.6B₩2.2B₩2.3B3.0%6.3%33.0%
2026.03₩78.9B₩5B₩6.1B6.4%13.6%43.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On an annual basis, revenue for the fiscal year ended March 2026 was KRW 78.9 billion, up 8.6% year on year. The fiscal year ended March 2024, at KRW 67.9 billion, was the low point, and revenue then grew for two consecutive years to KRW 72.6 billion and KRW 78.9 billion.

Operating performance moved from an operating loss of KRW 4.12 billion in the fiscal year ended March 2023 to operating profit of KRW 236 million in the fiscal year ended March 2024. It then rose to KRW 2.21 billion, up 836.5%, and to KRW 5.02 billion, up 127.0%, in the fiscal year ended March 2026.

The operating margin improved from -5.6% in fiscal 2023 to 6.4% in fiscal 2026. A media report attributed the recovery partly to dropping low-priced, volume-driven contracts and expanding add-on service revenue.

Profit attributable to controlling shareholders moved from a net loss of KRW 9.59 billion in fiscal 2023 to KRW 6.09 billion in fiscal 2026, and the filing shows net profit including non-controlling interests at the same amount.

Operating cash flow, however, went from KRW 10.9 billion in fiscal 2025 to -KRW 1.24 billion in fiscal 2026, creating a gap between reported profit and cash generation. The debt ratio fell from 73.5% in fiscal 2023 to 34.7% in fiscal 2024, then rose to 43.4% in fiscal 2026.

At the end of March 2026, total equity was KRW 44.8 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 19.4 billion.

Quarterly revenue rose from KRW 17.1 billion in the third quarter of 2025 to KRW 26.1 billion in the first quarter of 2026, then eased to KRW 20.5 billion and KRW 21 billion.

Operating profit was KRW 1.71 billion in the first quarter of 2026, KRW 276 million in the second quarter and KRW 1.37 billion in the third quarter. Profit attributable to controlling shareholders fell from KRW 2.27 billion to KRW 723 million before the third quarter swung to a loss of KRW 1.14 billion.

Operating profit rose in the third quarter while the company posted a loss attributable to shareholders, so the non-operating and tax lines in the quarterly report are the next point to verify.

Whether the first-quarter revenue spike reflected the timing of a specific installation project should also be checked in the segment notes. Over the most recent four quarters, profit attributable to controlling shareholders totaled KRW 3.37 billion.

05

Industry analysis

Demand for the company's products comes from hospitals' digital transformation and expanding use of medical data. Statista projects the global digital health market at about USD 181.25 billion in 2026, growing at an annual rate of 8.44% through 2031.

In Korea, the company cites a public hospital information system AI cloud transition support project, run with the Ministry of Science and ICT and NIA, as a growth axis.

That project has been paused temporarily over disputes between the agency and bidders about eligibility, and industry observers see a resumed selection process by year-end as an opportunity.

In the Middle East, a high rate of insurance claim deductions at hospitals has increased demand for revenue cycle management, which the company cites as a reason to expand its platform.

Structurally, installation revenue reflects order gaps quickly, while platform revenue builds up recurring sales as customers and services are added, so the two businesses move differently.

On competition, the company points to its combination of an on-premise HIS for large hospitals and a cloud HIS for small and mid-sized hospitals as its differentiator, but that is the company's own position, and independent market-share data was not located.

The company's view that physician shortages will raise demand for AI hospital platforms is also its own market outlook.

06

Outlook

At its August 2026 investor briefing, the company said overseas revenue could exceed KRW 20 billion in the fiscal year ending March 2027. It also set a goal of lifting the operating margin from about 7% in the fiscal year ended March 2026 to double digits in the following year.

It expects its overseas subsidiary to return to profit, which it says would improve net profit. The target for platform revenue to reach 50% or more of the total is reported as 2030 in one account and 2029 in another, so the original wording in the company's investor materials should be checked.

A media report said the company is aiming to pass KRW 100 billion in annual revenue for the first time, citing large public and hospital HIS wins and a contract with a Saudi private hospital group worth more than KRW 10 billion.

The same report said the Saudi private hospital project is being built toward operation in the first quarter of 2027. The veterans hospital HIS project carries a construction deadline of April 30, 2027.

For the Bundang Seoul National University Hospital outsourced operation contract, a correction filing on November 17, 2026 raised the contract amount to KRW 24.89 billion and extended the end date to January 31, 2027.

The company also plans cloud HIS supply to a Japanese university hospital and new projects in Southeast Asia and Africa. Whether these translate into orders and revenue will become visible in future quarterly filings.

07

Valuation

PER
24.6×
PBR
1.9×
ROE
8.2%
EPS
₩247
BPS
₩3,168
Dividend per share
₩0

The current multiples are calculated on profit attributable to controlling shareholders over the most recent four quarters, which totaled KRW 3.37 billion, a small base.

With profit this small, the earnings-based multiple moves sharply with the share price and with quarterly earnings swings, so quarterly profit trends should be read alongside it.

In the fiscal year ended March 2023 the company was loss-making, so an earnings-based multiple was not meaningful; it became comparable only after the return to profit in the fiscal year ended March 2024. The price-to-book ratio is above 1x, meaning the market is valuing the shares at a premium to book value.

Because all KRW 44.8 billion of equity is attributable to controlling shareholders, the book value comparison is straightforward. The dividend yield is below the industry average, and any change in shareholder return policy would appear in future periodic disclosures.

Compared with listed peers in the same sector, the earnings scale and multiple range differ, so a fair reading pairs the multiple with the trend of earnings recovery rather than a simple peer comparison. When quarterly profit swings as it did in the third quarter of 2026, the calculated multiple will also swing.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Sustained annual profit recovery

Operating profit has risen for two consecutive fiscal years since returning to profit in the fiscal year ended March 2024, and the operating margin reached 6.4% in fiscal 2026. Profit attributable to controlling shareholders also rose to KRW 6.09 billion. Profit growth outpacing revenue growth is consistent with the company's shift away from low-priced contracts.

Platform and overseas revenue expansion

Platform revenue for April to June 2026 rose from KRW 1.7 billion to KRW 3.7 billion, while consolidated revenue for the same period increased from KRW 15.9 billion to KRW 20.5 billion.

Overseas revenue was KRW 9.8 billion in fiscal 2026, and the company said it signed a contract of more than KRW 10 billion with a Saudi private hospital group covering six facilities. It also plans to add six new Middle East customers this year.

Public hospital references and external recognition

The company is building next-generation HIS systems for six veterans hospitals and three long-term care hospitals, and says its HIS products are used at 89 hospitals.

It was named to the 2026 World's Top HealthTech Companies list in September 2026 and, according to the company, received the top rating in the health information and management category. These references could serve as a base for converting existing customers to cloud systems.

09

Bear factors

Third-quarter 2026 swing to a loss

Profit attributable to controlling shareholders swung to a loss of KRW 1.14 billion in the third quarter of 2026, from a profit of KRW 723 million in the second quarter and from a profit a year earlier.

Operating profit recovered from KRW 276 million to KRW 1.37 billion, so the gap between operating and net results is the issue. With a four-quarter total of KRW 3.37 billion, quarterly swings carry a large weight.

Operating cash flow turning negative

Operating cash flow went from KRW 10.9 billion in fiscal 2025 to -KRW 1.24 billion in fiscal 2026. Against profit attributable to controlling shareholders of KRW 6.09 billion in the same year, cash conversion weakened. The debt ratio also rose from 33.0% to 43.4% over the same period.

Volatility of the installation-led model

The company itself describes its large-hospital installation business as one that requires new orders once each project ends. With platform revenue at 18% of the total in fiscal 2026, the platform is not yet large enough to offset gaps in installation revenue.

Revenue falling from KRW 26.1 billion in the first quarter of 2026 to KRW 20.5 billion in the second shows that volatility.

10

Risk factors

Related-party and single-contract concentration

A correction filed on November 17, 2026 raised the Bundang Seoul National University Hospital contract to KRW 24.89 billion, equal to 34.0% of recent revenue on the filing's basis. The filing lists that hospital as a related company of the largest shareholder.

A 2025 quarterly report also showed a sharp increase in receivables from a related Saudi company. High related-party exposure makes contract terms and renewals more consequential for results.

Policy project timing risk

The HIS cloud transition demonstration project has been suspended for the time being over eligibility disputes between the agency and bidders. If the selection process does not resume by year-end, the visible growth of the cloud HIS business could be delayed.

Because the company treats this project as a core axis of its platform shift, schedule slippage would directly affect the pace of its targets.

Execution risk in overseas projects

The overseas revenue target of more than KRW 20 billion for the fiscal year ending March 2027 requires a large increase from KRW 9.8 billion in fiscal 2026. The timing and size of revenue from the Saudi private hospital contract and the planned Japanese supply have not yet been confirmed in filings.

The overseas subsidiary's return to profit is also still a company projection, so progress needs to be verified against quarterly results.

11

What to watch next

  1. End of December 2026

    Whether the selection of operators for the HIS cloud transition demonstration project resumes. A resumption would create a base for the public HIS cloud transition to feed into results.

  2. January 31, 2027

    The extended end date of the Bundang Seoul National University Hospital outsourced operation contract. Whether a follow-on contract is signed and on what terms bears directly on related-party concentration and revenue stability.

  3. Mid-February 2027 (statutory filing deadline basis)

    The quarterly report for the fourth quarter of 2026 (October to December). It will show whether the gap between operating profit and profit attributable to controlling shareholders seen in the third quarter reflects non-operating items or tax, and whether operating cash flow recovers.

  4. April 30, 2027

    The construction deadline for the veterans hospital next-generation HIS project. Completion on schedule and the progress of recognized revenue will indicate the trajectory of installation revenue.

  5. End of June 2027 (statutory filing deadline basis)

    The annual report for the fiscal year ending March 2027. It will show whether the overseas revenue target of more than KRW 20 billion, the double-digit operating margin goal and the change in platform revenue share were achieved.

12

Overall view

For the fiscal year ended March 2026, ezCaretech reported revenue of KRW 78.9 billion and operating profit of KRW 5.02 billion, improving both scale and profitability.

Operating profit and profit attributable to controlling shareholders have risen for two consecutive fiscal years since the return to profit in fiscal 2024, and the operating margin moved from -5.6% to 6.4%.

On the other side, the third quarter of 2026 swung to a net loss attributable to controlling shareholders of KRW 1.14 billion, and operating cash flow in fiscal 2026 turned negative at -KRW 1.24 billion.

Platform revenue rose to KRW 3.7 billion in April to June 2026 and the company has set overseas targets, but platform revenue remains 18% of the total. The related-party character of the Bundang contract and the pause in the HIS cloud project are also variables to weigh.

Strengths include the earnings recovery and the expansion of platform and overseas sales, while weaknesses include quarterly profit volatility, weaker cash generation, and dependence on specific contracts and policy timing.

The next checkpoints are the fourth-quarter 2026 quarterly report and the annual report for the fiscal year ending March 2027, which will show whether non-operating items and overseas targets are being met.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. etnews.com
  2. medipana.com
  3. ezcaretech.com
  4. paxetv.com
  5. m.news.nate.com
  6. comp.fnguide.com
  7. catch.co.kr
  8. saramin.co.kr
  9. kind.krx.co.kr
  10. ezcaretech.com
  11. hankyung.com
  12. joongangenews.com
  13. m.etnews.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. vegannews.co.kr
  17. ezcaretech.com
  18. v.daum.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis